In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CNS Therapeutics, Inc.

http://www.gablofen.com/

Latest From CNS Therapeutics, Inc.

Spine Market: Making A Comeback

In spite of increasing price pressure, the $9 billion global spine market is projected to see low-single-digit growth in the next few years. Driving growth are the pure-play spine companies targeting high-growth segments such as minimally invasive surgery, expandable interbody cases, cervical discs, and deformity.

Medical Device

Strategy Of A Corporate Split: An Interview With Mallinckrodt’s Mark Trudeau and Matt Harbaugh

CEO-designate and CFO for the Mallinckrodt specialty pharma spin-out from Covidien discuss the strategy for differentiating its products in a competitive analgesic space. Despite a goal of becoming a leading specialty pharma, the new company does not plan to divest its imaging or active pharmaceutical ingredient businesses.

BioPharmaceutical North America

How The Midwest Was Won: Creating A New Epicenter For Device Innovation And Investment

Talent, innovation, world-class research institutions, established supply chains, and a lower cost of doing business – what else do you need to launch and grow a device company? Well, capital, for one. Players in the Midwest are working in a variety of ways to draw entrepreneurs and venture money to the region, and their efforts are reaping positive results.

Medical Device United States

Deals In Depth: September 2012

Two of September’s top biopharma alliances were deals for cancer candidates. Valeant paid over $2 billion for dermatology company Medicis. Biopharma financing totaled $608 million, and device funding dipped to $151 million.

Medical Device BioPharmaceutical
See All

Company Information

UsernamePublicRestriction

Register